Journal of Inflammation (Oct 2010)

HE3286, an oral synthetic steroid, treats lung inflammation in mice without immune suppression

  • Frincke James M,
  • White Steven K,
  • van Heeckeren Anna M,
  • Mangano Katia,
  • Nicoletti Ferdinando,
  • Pieters Raymond,
  • Wang Angela,
  • Conrad Douglas,
  • Reading Christopher L,
  • Stickney Dwight,
  • Auci Dominick L

DOI
https://doi.org/10.1186/1476-9255-7-52
Journal volume & issue
Vol. 7, no. 1
p. 52

Abstract

Read online

Abstract Background 17α-Ethynyl-5-androsten-3β, 7β, 17β-triol (HE3286) is a synthetic derivative of an endogenous steroid androstenetriol (β-AET), a metabolite of the abundant adrenal steroid deyhdroepiandrosterone (DHEA), with broad anti-inflammatory activities. We tested the ability of this novel synthetic steroid with improved pharmacological properties to limit non-productive lung inflammation in rodents and attempted to gauge its immunological impact. Methods and Results In mice, oral treatment with HE3286 (40 mg/kg) significantly (p in vivo (ovalbumin immunization). When mice treated for two weeks with HE3286 were challenged with K. pneumoniae, nearly identical survival kinetics were observed in vehicle-treated, HE3286-treated and untreated groups. Conclusions HE3286 represents a novel, first-in-class anti-inflammatory agent that may translate certain benefits of β-AET observed in rodents into treatments for chronic inflammatory pulmonary disease.